

IHCP *bulletin*

Note: This bulletin has been updated.
See IHCP Bulletin [BT202204](#).



INDIANA HEALTH COVERAGE PROGRAMS BT202202 JANUARY 5, 2022

IHCP COVID-19 Response: IHCP revises remdesivir administration reimbursement policy

Effective Jan. 1, 2022, the Indiana Health Coverage Programs (IHCP) will reimburse hospital providers for the administration of remdesivir (brand name Veklury) outside of a hospital inpatient setting, if the healthcare setting is capable of providing acute care comparable to inpatient hospital care.

Remdesivir has not been issued a drug-specific Healthcare Common Procedure Coding System (HCPCS) code (at the date of this publication). For this reason, and until a HCPCS code number is assigned, providers should bill for remdesivir using HCPCS code J3490 – *Unclassified drugs* for claims with dates of service (DOS) on or after Jan. 1, 2022.

Reimbursement and billing information

Note: When billing a “not otherwise classified” code like J3490, the HCPCS quantity is equal to 1.

Providers should follow these reimbursement and billing guidelines:

- J3490 must be billed with the National Drug Code (NDC) of the product administered. The NDC of the remdesivir administered must be submitted with the following information:
 - For NDC 61958-2901-01:
 - ◆ Unit of measure (UOM) is UN (vial).
 - ◆ NDC quantity is equal to the number of vials administered.
 - For NDC 61958-2901-02:
 - ◆ UOM is UN (vial).
 - ◆ NDC quantity is equal to the number of vials administered.
 - For NDC 61958-2902-01:
 - ◆ UOM is ML (milliliter).
 - ◆ NDC quantity is equal to the number of MLs administered.
- Pricing calculation: 105% of the wholesale acquisition cost (WAC) of the NDC billed by the provider
- Prior authorization (PA): None required



Providers can refer to the following resources for Indiana Department of Health specific guidelines for remdesivir:

- [Indiana Department of Health \(IDOH\) Treatment in a Medical Setting Guidelines](#)
 - [Outpatient Remdesivir Treatment for Nonhospitalized COVID-19 Patients at Risk for Progression to Severe Disease](#)

Also, providers can refer to these additional resources:

- [Veklury Prescribing Information](#)
- [Centers for Disease Control and Prevention \(CDC\) COVID-19 Therapeutic Options](#)
- [National Institute for Health \(NIH\) COVID-19 Treatment Guidelines](#)

Reimbursement and billing information apply to services delivered under the fee-for-services (FFS) delivery system. Questions about FFS reimbursement and billing should be directed to Gainwell Technologies at 800-457-4584, option 7. Individual MCEs establish and publish reimbursement and billing information within the managed care delivery system. Questions about managed care reimbursement and billing should be directed to the MCE with which the member is enrolled.



TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without photos, is available for your convenience.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [Bulletins](#) page of the IHCP provider website at

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#)

